USA TODAY Co., Inc. (TDAY)
Live price chart, market sentiment, and community perspectives for USA TODAY Co., Inc. (NYSE: TDAY).
Live price chart, market sentiment, and community perspectives for USA TODAY Co., Inc. (NYSE: TDAY).
Dealer gamma exposure on TDAY creates elevated volatility near the current strike cluster. Not adding exposure until after the backlog data clears.
On our desk, TDAY is currently filed strictly as a hold because the core turnaround remains unconvincing. Total revenue fell 8.3% to $536.3 million in Q2 2026, and digital advertising keeps sliding by over 9%. While management deserves credit for cutting operating expenses by roughly 8% and expanding free cash flow to $19.6 million, the primary reason to maintain exposure is the Google antitrust litigation. With liability largely established, the market is starting to price in the damages phase as a distinct, high-value option that could override the underlying publishing headwinds.
Looking at the Q2 earnings print and the 10-Q filing, TDAY's fundamental transition hinges on shifting away from search referrals and leaning heavily into first-party audiences, social, video, newsletters, and AI monetization via partnerships like Palantir and DeeperDive. Digital-only ARPU jumped 34.4% to $10.47, proving that culling low-value subscribers and ending deep discounting can protect profitability. However, future revenue is still projected to decline at a 2.3% annualized rate, meaning operational contraction remains a baseline structural risk for long-term holders.
When evaluating TDAY's fundamental model from a quantitative standpoint, analysts must separate the shrinking legacy cost structure from volatile growth vectors. Digital Other revenue managed a 20.2% increase to $20.4 million driven by syndication, commerce, and early-stage AI licensing agreements, but content licensing remains inherently lumpy. Until AI licensing syndication scales past its current small base to reliably offset structural search and advertising declines, earnings growth estimates of 35.9% per year will rely heavily on cost controls rather than top-line expansion.
Explore plasma cleansing, somatic organ swaps, and BCI.